Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

Bio Blast Pharma Ltd. (ORPN)

(Delayed Data from NSDQ)

$11.50 USD

0.00 (0.00%)

Updated Mar 25, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Enlivex Therapeutics Ltd. [ORPN]

Reports for Purchase

Showing records 1 - 20 ( 68 total )

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 1

10/10/2017

Pages: 10

ValuEngine Detailed Valuation Report for ORPN

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 2

07/16/2017

Pages: 4

We are terminating our coverage due to reallocation of resources within the research department

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 3

07/16/2017

Pages: 4

We are hereby terminating our coverage due to reallocation of resources within the research department.

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 4

05/24/2017

Pages: 3

Corrected - Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 5

05/24/2017

Pages: 4

We are dropping coverage of ORPN shares to reallocate our research resources.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 6

05/24/2017

Pages: 3

Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 7

12/19/2016

Pages: 4

We are transferring coverage of ORPN to Sa''ar Yaniv, due to the departure of the covering analyst and placing shares Under Review

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 8

12/09/2016

Pages: 4

Lowering Price Target to $9 From $19 Based on Higher Discount Rate for Trehalose; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 9

12/09/2016

Pages: 4

Lowering Price Target to $9 From $19 Based on Higher Discount Rate for Trehalose; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 10

11/30/2016

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 11

11/29/2016

Pages: 7

3Q16 Results; Gearing Up for OPMD Phase IIb

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 12

11/28/2016

Industry Report

Pages: 10

ROTH Healthcare Monthly - Longing for Better Blood at ASH

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 13

10/25/2016

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 14

10/24/2016

Pages: 4

MTD Study Points to 2x Dosing Above HOPEMD; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 15

09/13/2016

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 16

09/12/2016

Pages: 8

Extension Study Data Continue to Point in Right Direction for OPMD

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 17

08/26/2016

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 18

08/25/2016

Pages: 7

2Q16 Results; Looking to Build on HOPEMD Efficacy Next Year

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 19

07/11/2016

Pages: 4

Reducing Price Target to $19 Per Share Based on Outlook; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Enlivex Therapeutics Ltd.

Industry: Medical - Drugs

Record: 20

07/11/2016

Pages: 4

Reducing Price Target to $19 Per Share Based on Outlook; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

previous
1
2
3
4
next

// eof